| Autor: |
Reddy, R., Pannu, S., Fiumara, K., Kahn, J., Rosmarin, D. |
| Předmět: |
|
| Zdroj: |
British Journal of Dermatology; Mar2021, Vol. 184 Issue 3, p559-561, 3p |
| Abstrakt: |
In a subset analysis of the patients who failed primary guselkumab treatment, PGA*BSA was 20-3 before risankizumab treatment and 8-6 after treatment, demonstrating a 57-6% decrease. Although patients who failed primary guselkumab treatment seem to have a less effective response to risankizumab than the patients who failed secondary treatment with guselkumab, there was still a notable reduction in PGA*BSA. For the patients who failed secondary treatment, the PGA*BSA was 36-0 before risankizumab treatment and 3-6 after treatment, showing a 90% average decrease. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text